These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 24457342)

  • 41. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.
    Murray M; Hogg RS; Lima VD; May MT; Moore DM; Abgrall S; Bruyand M; D'Arminio Monforte A; Tural C; Gill MJ; Harris RJ; Reiss P; Justice A; Kirk O; Saag M; Smith CJ; Weber R; Rockstroh J; Khaykin P; Sterne JA;
    HIV Med; 2012 Feb; 13(2):89-97. PubMed ID: 21819529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD4+:CD8+ T Cell Ratio Normalization and the Development of AIDS Events in People with HIV Starting Antiretroviral Therapy.
    Okhai H; Vivancos-Gallego MJ; Hill T; Sabin CA
    AIDS Res Hum Retroviruses; 2020 Oct; 36(10):808-816. PubMed ID: 32664736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression.
    Caby F; Guihot A; Lambert-Niclot S; Guiguet M; Boutolleau D; Agher R; Valantin MA; Tubiana R; Calvez V; Marcelin AG; Carcelain G; Autran B; Costagliola D; Katlama C
    Clin Infect Dis; 2016 May; 62(10):1297-1303. PubMed ID: 26908792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.
    Donnell D; Baeten JM; Kiarie J; Thomas KK; Stevens W; Cohen CR; McIntyre J; Lingappa JR; Celum C;
    Lancet; 2010 Jun; 375(9731):2092-8. PubMed ID: 20537376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of monitoring antiretroviral therapy response in HIV-1 infection using CD4+ T cell count at long-term intervals.
    Vogler IH; Alfieri DF; Gianjacomo HDB; Almeida ERD; Reiche EMV
    Cad Saude Publica; 2018 Oct; 34(10):e00009618. PubMed ID: 30365742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.
    Nicolás D; Esteve A; Cuadros A; Campbell CNJ; Tural C; Podzamczer D; Murillas J; Homar F; Segura F; Force L; Vilaró J; Masabeu À; Garcia I; Mercadal J; Montoliu A; Ferrer E; Riera M; Cifuentes C; Ambrosioni J; Navarro G; Manzardo C; Clotet B; Gatell JM; Casabona J; Miró JM; ; Murillas J; Manzardo C; Masabeu A; Mercadal J; Cifuentes C; Dalmau D; Domingo P; Falcó V; Curran A; Agustí C; Montoliu A; Pérez I; Curto J; Gargoulas F; Gómez A; Rubia JC; Zamora L; Blanco JL; Garcia-Alcaide F; Martínez E; Mallolas J; Llibre JM; Sirera G; Romeu J; Jou A; Negredo E; Saumoy M; Imaz A; Bolao F; Cabellos C; Peña C; DiYacovo S; Van Den Eynde E; Sala M; Cervantes M; Amengual MJ; Navarro M; Segura V; Barrufet P; Molina J; Alvaro M; Payeras T; Gracia Mateo M; Fernández J
    Clin Infect Dis; 2016 Jun; 62(12):1578-1585. PubMed ID: 27126346
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa.
    Hoffmann CJ; Schomaker M; Fox MP; Mutevedzi P; Giddy J; Prozesky H; Wood R; Garone DB; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2013 May; 63(1):34-41. PubMed ID: 23344547
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunovirological discordance among female sex workers who start antiretroviral therapy in Burkina Faso.
    Bazié WW; Somé DY; Traoré IT; Sanon A; Konaté I; Tassembedo S; Taofiki AO; Kania D; Ouédraogo A; Vuylsteke B; Gilbert C; Meda N; Ouédraogo AS; Nagot N
    BMC Infect Dis; 2022 Feb; 22(1):117. PubMed ID: 35114959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients.
    Maskew M; Brennan AT; Westreich D; McNamara L; MacPhail AP; Fox MP
    J Womens Health (Larchmt); 2013 Feb; 22(2):113-20. PubMed ID: 23350862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
    ; Lodwick RK; Sabin CA; Porter K; Ledergerber B; van Sighem A; Cozzi-Lepri A; Khaykin P; Mocroft A; Jacobson L; De Wit S; Obel N; Castagna A; Wasmuth JC; Gill J; Klein MB; Gange S; Riera M; Mussini C; Gutiérrez F; Touloumi G; Carrieri P; Guest JL; Brockmeyer NH; Phillips AN
    Lancet; 2010 Jul; 376(9738):340-5. PubMed ID: 20638118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of Antiretroviral Therapy on CD4+ Cell Count, HIV Viral Load and Death in a South African Cohort: A Modelling Study.
    Shoko C; Chikobvu D; Bessong PO
    Pak J Biol Sci; 2020 Mar; 23(4):542-551. PubMed ID: 32363840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.
    Fox MP; Sanne IM; Conradie F; Zeinecker J; Orrell C; Ive P; Rassool M; Dehlinger M; van der Horst C; McIntyre J; Wood R
    AIDS; 2010 Aug; 24(13):2041-50. PubMed ID: 20613459
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N; Uthman OA; Rutherford GW
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial.
    Boatman JA; Baker JV; Emery S; Furrer H; Mushatt DM; Sedláček D; Lundgren JD; Neaton JD;
    J Acquir Immune Defic Syndr; 2019 May; 81(1):10-17. PubMed ID: 30664075
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
    del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
    Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV.
    Helleberg M; Kronborg G; Larsen CS; Pedersen G; Pedersen C; Obel N; Gerstoft J
    Clin Infect Dis; 2013 Jul; 57(2):314-21. PubMed ID: 23575194
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of HIV-1 Subtype on the Time to CD4+ T-Cell Recovery in Combination Antiretroviral Therapy (cART)-Experienced Patients.
    Chow WZ; Lim SH; Ong LY; Yong YK; Takebe Y; Kamarulzaman A; Tee KK
    PLoS One; 2015; 10(9):e0137281. PubMed ID: 26335136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.